Atom Investors LP Has $1.87 Million Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Atom Investors LP trimmed its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 66.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,275 shares of the medical equipment provider’s stock after selling 34,292 shares during the period. Atom Investors LP’s holdings in Zimmer Biomet were worth $1,865,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Gradient Investments LLC boosted its position in shares of Zimmer Biomet by 17.3% during the 2nd quarter. Gradient Investments LLC now owns 130,350 shares of the medical equipment provider’s stock worth $14,147,000 after acquiring an additional 19,224 shares in the last quarter. National Pension Service lifted its stake in Zimmer Biomet by 3.8% during the third quarter. National Pension Service now owns 369,547 shares of the medical equipment provider’s stock worth $39,893,000 after purchasing an additional 13,612 shares during the last quarter. River Global Investors LLP boosted its holdings in shares of Zimmer Biomet by 31.3% in the 3rd quarter. River Global Investors LLP now owns 21,084 shares of the medical equipment provider’s stock valued at $2,276,000 after purchasing an additional 5,030 shares in the last quarter. Border to Coast Pensions Partnership Ltd increased its stake in shares of Zimmer Biomet by 4.5% in the 3rd quarter. Border to Coast Pensions Partnership Ltd now owns 155,254 shares of the medical equipment provider’s stock valued at $16,711,000 after purchasing an additional 6,623 shares during the last quarter. Finally, Point72 Europe London LLP acquired a new position in shares of Zimmer Biomet during the 2nd quarter worth $7,402,000. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Trading Down 1.4 %

NYSE:ZBH opened at $110.50 on Tuesday. Zimmer Biomet Holdings, Inc. has a 52 week low of $101.47 and a 52 week high of $133.90. The firm’s fifty day moving average is $107.29 and its 200-day moving average is $109.30. The firm has a market cap of $22.00 billion, a P/E ratio of 21.01, a P/E/G ratio of 2.06 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.74. The firm had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The business’s revenue was up 4.1% compared to the same quarter last year. During the same period last year, the business posted $1.65 EPS. Equities analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. UBS Group decreased their target price on Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating on the stock in a research report on Thursday, August 8th. Oppenheimer decreased their price target on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a report on Tuesday, October 15th. BTIG Research dropped their price objective on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a research note on Thursday, October 3rd. JPMorgan Chase & Co. decreased their target price on shares of Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating on the stock in a research note on Monday, September 16th. Finally, Raymond James dropped their price target on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a research note on Monday, October 14th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $123.22.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.